Accéder au contenu
Merck
Toutes les photos(1)

Documents

H-001

Supelco

Hydrochlorothiazide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C7H8ClN3O4S2
Numéro CAS:
58-93-5
Poids moléculaire :
297.74
Numéro CE :
200-659-6
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

Clé InChI

JZUFKLXOESDKRF-UHFFFAOYSA-N

Informations sur le gène

human ... SLC12A3(6559)

Catégories apparentées

Description générale

Hydrochlorothiazide is a calcium-sparing diuretic used for treatment of edema and hypertension. A thiazide derivative, hydrochlorothiazide is sold under the trade names Microzide® and Aquazide H. This Certified Spiking Solution® is suitable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Microzide is a registered trademark of Watson Laboratories, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

Dexamethasone solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

D-085

Dexamethasone solution

Salbutamol

Sigma-Aldrich

S8260

Salbutamol

Phenacetin melting point standard Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1094

Phenacetin melting point standard

Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension.
Brent Egan et al.
Journal of hypertension, 31(2), 259-260 (2013-01-11)
Yoshihisa Hanayama et al.
Acta medica Okayama, 66(6), 449-459 (2012-12-21)
Angiotensin receptor blockers (ARBs) are the first-line antihypertensive agents. In clinical practice, it is often difficult to achieve the recommended blood pressure level by ARBs in their ordinal dosages alone. This study examined the practical efficacy of a combination therapy
Michael A Weber et al.
Lancet (London, England), 381(9866), 537-545 (2012-12-12)
In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascular event rates have been reported in patients of normal weight compared with obese individuals. As a prespecified analysis of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living
Alexander V Murray et al.
Journal of clinical hypertension (Greenwich, Conn.), 14(12), 821-827 (2012-12-05)
Combination antihypertensive therapies are recommended to attain blood pressure (BP) targets especially in high-risk patients in whom rapid and pronounced BP control is essential. This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination
M Al Qahtani et al.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 24(2), 281-285 (2013-03-30)
Hyponatremia is the most frequently encountered electrolyte abnormality among hospitalized patients and thiazide users. In this large single-center retrospective study, we aim to determine the prevalence and risk factors of hyponatremia among patients at the King Abdulaziz Medical City (KAMC)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique